Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

verisfield ΜΟΝΟΠΡΟΣΩΠΗ Α.Ε. Δ.Τ. verisfield Βύρωνος 8 & Γυθείου, Χαλάνδρι 152 31 210.7475196 - salicylic acid; fluorouracil - cut.sol (ΔΕΡΜΑΤΙΚΟ ΔΙΑΛΥΜΑ) - (100+5)mg/g - salicylic acid 100mg; fluorouracil 5mg - wart and anti-corn preparations; fluorouracil, combinations

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

merck a.e. - tegafur, combinations - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - (100+224)mg/cap - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

nordic group b.v., netherlands - tegafur, combinations - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - (15+4,35+11,8)mg/cap - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

nordic group b.v., netherlands - tegafur, combinations - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - (20+5,8+15,8)mg/cap - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

nordic group b.v., netherlands - tegafur, gimeracil, oteracil - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - (15+4,35+11,8)mg/cap - 0017902237 - tegafur - 15.000000 mg; 0103766252 - gimeracil - 4.350000 mg; 002207752 - oteracil - 11.800000 mg - tegafur, combinations

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

nordic group b.v., netherlands - tegafur, gimeracil, oteracil - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - (20+5,8+15,8)mg/cap - 0017902237 - tegafur - 20.000000 mg; 0103766252 - gimeracil - 5.800000 mg; 002207752 - oteracil - 15.800000 mg - tegafur, combinations

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

les laboratoires servier - trifluridine, tipiracil υδροχλωρική - Πρωτοπλαστικά νεοπλάσματα - Αντινεοπλασματικοί παράγοντες - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

nordic group b.v. - tegafur, gimeracil, oteracil - Νεοπλάσματα του στομάχου - Αντινεοπλασματικοί παράγοντες - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - cedazuridine, decitabine - Λευχαιμία, μυελοειδής - Αντινεοπλασματικοί παράγοντες - inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for standard induction chemotherapy.